Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Aporo Biomedical has signed an exclusive global licensing agreement with mNemoscience for its proprietary biodegradable shape memory polymers or BIO-SMP.
Subscribe to our email newsletter
Aporo claims to provide significant clinical value by delivering novel transcatheter devices that close defects and then biodegrade over time, leaving behind no permanent implant. Initially, Aporo will use these materials to treat patent foramen ovale, a type of structural heart disease.
In the future, the company intends to use the polymers in devices to treat atrial septal defect, another structural heart disease, and for vascular closure after catheter-based interventional procedures.